Patents by Inventor Joseph Andreas

Joseph Andreas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250131201
    Abstract: A system and method for AI-assisted conversation utilize a biosensor to receive biosignals, which are analyzed by the perception engine. The engine generates context tags and text descriptions from multimodal sensory inputs and biosignal analysis. This information is then used by the conversation engine, along with memory engine data (conversation history, biographical background, keywords), to generate prompts for a language model. These prompts are displayed to a user through a computing device that presents various conversation features like communication history, context data, and selected content. The system enables interactive AI-assisted conversations between humans and machines or other humans.
    Type: Application
    Filed: October 18, 2024
    Publication date: April 24, 2025
    Applicant: Cognixion Corporation
    Inventors: Christopher Jason Ullrich, Carl Hagmann, Cole Heiner, Daniela Friedson-Trujillo, Joseph Andreas Forsland
  • Patent number: 12180552
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumours and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.
    Type: Grant
    Filed: August 23, 2021
    Date of Patent: December 31, 2024
    Assignee: Byondis B.V.
    Inventors: Gerardus Joseph Andreas Ariaans, Rudy Gerardus Elisabeth Coumans
  • Publication number: 20240419246
    Abstract: There are disclosed herein systems and methods for human agency support and facilitation through an integrated use of context information, historical work product, biosensors, explicit user input and a generative AI or generalist agent. The system comprises input means, tokenization, a generative AI or generalist agent and an output stage capable of enacting agency on a user's behalf using output tokens from the language model.
    Type: Application
    Filed: June 15, 2023
    Publication date: December 19, 2024
    Applicant: Cognixion Corporation
    Inventors: Christopher Jason Ullrich, Joseph Andreas Forsland, Benjamin Cortens, Carl Hagmann, Lucas Carl Steuber
  • Publication number: 20240345406
    Abstract: An electrode assembly and a system including it are disclosed. The electrode assembly includes an electrode body with arc rail(s) attached to and extending from the electrode body. The arc rail(s) include at least one sensing element for sensing or stimulating the state of a particular property of a selected subject area when applied by the arc rail to that area. The arc rail is so disposed in relation to the electrode body as to be disposed at a non-perpendicular angle to the subject area when the electrode assembly is applied to the selected subject area. The system includes an analog front end (AFE) configured to receive output signals from at least one electrode assembly and transmit the output signals to a digital module for processing. The system also includes an accessory strap with sockets to receive electrode assemblies and deliver their outputs to the AFE.
    Type: Application
    Filed: April 11, 2024
    Publication date: October 17, 2024
    Applicant: Cognixion Corporation
    Inventors: Joseph Andreas Forsland, Christopher Jason Ullrich
  • Publication number: 20240288940
    Abstract: A method and system are disclosed using steady-state motion visual evoked potential stimuli in an augmented reality environment. Requested stimuli data are received from a user application on a smart device. Sensor data and other context data are also received, where other context data includes data that is un-sensed. The requested stimuli data are transformed into modified stimuli based on the sensor data, and the other context data. Modified stimuli and environmental stimuli are presented to the user with a rendering device configured to mix the modified stimuli and the environmental stimuli, thereby resulting in rendered stimuli. Biosignals generated in response to the rendered stimuli are received from the user to a wearable biosignal sensing device. Received biosignals are classified based on the modified stimuli, resulting in a classified selection, which is returned to the user application.
    Type: Application
    Filed: May 3, 2024
    Publication date: August 29, 2024
    Applicant: Cognixion Corporation
    Inventors: Sarah Pearce, Aravind Ravi, Jing Lu, Ning Jiang, Joseph Andreas Forsland, Christopher Jason Ullrich
  • Publication number: 20230308872
    Abstract: A system for transferring data via data packets includes a data transfer transceiver and a plurality of vehicles, the vehicles in each case having an on-board data receiver for receiving data packets transmitted by the data transfer transceiver. In order to enable a lighter bandwidth load in the data transfer, shorter computing times and lower computing capacities, the data transfer transceiver is configured to transmit the data packets by way of a broadcast transmission to the on-board data receivers of the plurality of vehicles.
    Type: Application
    Filed: March 17, 2023
    Publication date: September 28, 2023
    Applicant: Ford Global Technologies, LLC
    Inventors: Joseph Andreas Urhahne, Frederic Christen
  • Publication number: 20230274516
    Abstract: A method and system of a user interface device with dual-sided display which may include a system using a brain computer interface with an Augmented Reality (AR) headset. The user's intent is sent to the system, which processes, analyzes and maps the user's intent. An output corresponding to the user's intent is projected using the user interface device. This output is displayed on the user's side of the display. An image corresponding to the output is displayed on the observer's side of the display.
    Type: Application
    Filed: May 9, 2023
    Publication date: August 31, 2023
    Applicant: Cognixion Corporation
    Inventors: Joseph Andreas Forsland, Leonard Zerman
  • Patent number: 11584801
    Abstract: The present invention relates to antibodies against the human 5T4 oncofoetal antigen and corresponding antibody-drug conjugates that are suitable for testing in clinical trials. The antibodies are cross-reactive for humans and cynomolgus monkeys and exhibit an affinity for human 5T4 antigen which is in the same order of magnitude as their affinity for cynomolgus monkey 5T4 antigen. The invention further relates to the use of the antibodies and corresponding ADCs in the treatment of solid tumours and haematological malignancies.
    Type: Grant
    Filed: April 13, 2021
    Date of Patent: February 21, 2023
    Assignee: Byondis B.V.
    Inventors: Miranda Maria Cornelia Van Der Lee, Gerardus Joseph Andreas Ariaans, Jan Schouten, Marion Blomenrohr, Patrick Gerhard Groothuis, Rudy Gerardus Elisabeth Coumans
  • Publication number: 20210388115
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumours and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.
    Type: Application
    Filed: August 23, 2021
    Publication date: December 16, 2021
    Inventors: Gerardus Joseph Andreas ARIAANS, Rudy Gerardus Elisabeth COUMANS
  • Publication number: 20210317231
    Abstract: The present invention relates to antibodies against the human 5T4 oncofoetal antigen and corresponding antibody-drug conjugates that are suitable for testing in clinical trials. The antibodies are cross-reactive for humans and cynomolgus monkeys and exhibit an affinity for human 5T4 antigen which is in the same order of magnitude as their affinity for cynomolgus monkey 5T4 antigen. The invention further relates to the use of the antibodies and corresponding ADCs in the treatment of solid tumours and haematological malignancies.
    Type: Application
    Filed: April 13, 2021
    Publication date: October 14, 2021
    Inventors: Miranda Maria Cornelia VAN DER LEE, Gerardus Joseph Andreas ARIAANS, Jan SCHOUTEN, Marion BLOMENROHR, Patrick Gerhard GROOTHUIS, Rudy Gerardus Elisabeth COUMANS
  • Patent number: 11136633
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumours and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: October 5, 2021
    Assignee: Byondis B.V.
    Inventors: Gerardus Joseph Andreas Ariaans, Rudy Gerardus Elisabeth Coumans
  • Patent number: 11104968
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumours and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: August 31, 2021
    Assignee: Byondis B.V.
    Inventors: Gerardus Joseph Andreas Ariaans, Rudy Gerardus Elisabeth Coumans
  • Patent number: 11008400
    Abstract: The present disclosure relates to CDR defined antibodies targeting the 5T4 oncofoetal antigen (TPBG, 5T4, Wnt Activated Inhibitory Factor 1, WAIF1) which exhibit a binding affinity for human 5T4 antigen which is in the same order of magnitude as their affinity for cynomolgus monkey 5T4. Antibody-drug conjugates (ADCs), and their use in the treatment of human solid tumours and haematological malignancies are claimed.
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: May 18, 2021
    Assignee: Byondis B.V.
    Inventors: Miranda Maria Cornelia Van der Lee, Gerardus Joseph Andreas Ariaans, Jan Schouten, Marion Blomenrohr, Patrick Gerhard Groothuis, Rudy Gerardus Elisabeth Coumans
  • Patent number: 10694041
    Abstract: A number of phantom communication sessions and a number of contact center agents are assigned to a high priority contact center queue. The number of phantom communication sessions are greater than or equal to the number of assigned contact center agents. The high priority contact center queue is used for coordinating communication session routing with an external control application. A first contact center agent of the number of contact center agents is determined to be available. The first contact center agent is assigned to a first phantom communication session in response to determining that the first contact center agent is available. This results in a notification being sent to the external control application that the first contact center agent is available. This allows the external control application to coordinate routing of the communication session.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: June 23, 2020
    Assignee: Avaya Inc.
    Inventors: Valentine C. Matula, Joseph Andreas, Stephen Japuntich, Diego Klajner
  • Patent number: 10692382
    Abstract: Methods and devices assist in a parking maneuver of a vehicle. The vehicle includes a parking aid that produces a first signal. The first signal is perceptible in an interior of the vehicle during a parking maneuver. A signal property of the first signal is adapted to a currently prevailing distance of the vehicle from a parking obstruction. The first signal is converted into a second signal that is perceptible by an operator located outside the vehicle. The second signal is transmitted to the operator disposed outside the vehicle during a remotely-controlled performance of the parking maneuver.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: June 23, 2020
    Assignee: FORD GLOBAL TECHNOLOGIES, LLC
    Inventors: Joseph Andreas Urhahne, Robert Spahl
  • Publication number: 20190368000
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumours and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.
    Type: Application
    Filed: June 28, 2019
    Publication date: December 5, 2019
    Inventors: Gerardus Joseph Andreas ARIAANS, Rudy Gerardus Elisabeth COUMANS
  • Publication number: 20190367999
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumours and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.
    Type: Application
    Filed: June 28, 2019
    Publication date: December 5, 2019
    Inventors: Gerardus Joseph Andreas ARIAANS, Rudy Gerardus Elisabeth COUMANS
  • Patent number: 10494024
    Abstract: A motor vehicle is automatically forward or reverse parked into a perpendicular or transverse parking space. After the driver has stopped the motor vehicle, ahead of the parking space in a position that appears suitable to him/her for a direct parking procedure, has exited the motor vehicle and has started the method via a remote control, according to the disclosure the vehicle is automatically allowed to drive a short distance straight ahead. During the short distance of straight-ahead travel, the parking-space gateway is ascertained via an environment sensor system, from which a parking trajectory is calculated. At the end of the short distance of straight-ahead travel, the motor vehicle stops automatically and steers the front wheels into a position corresponding to the calculated parking trajectory.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: December 3, 2019
    Assignee: Ford Global Technologies, LLC
    Inventor: Joseph Andreas Urhahne
  • Patent number: 10407743
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumors and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: September 10, 2019
    Assignee: Synthon Biopharmaceuticals B.V.
    Inventors: Gerardus Joseph Andreas Ariaans, Rudy Gerardus Elisabeth Coumans
  • Publication number: 20190194346
    Abstract: The present disclosure relates to CDR defined antibodies targeting the 5T4 oncofoetal antigen (TPBG, 5T4, Wnt Activated Inhibitory Factor 1, WAIF1) which exhibit a binding affinity for human 5T4 antigen which is in the same order of magnitude as their affinity for cynomolgus monkey 5T4. Antibody-drug conjugates (ADCs), and their use in the treatment of human solid tumours and haematological malignancies are claimed.
    Type: Application
    Filed: November 24, 2016
    Publication date: June 27, 2019
    Inventors: Miranda Maria Cornelia VAN DER LEE, Gerardus Joseph Andreas ARIAANS, Jan SCHOUTEN, Marion BLOMENROHR, Patrick Gerhard GROOTHUIS, Rudy Gerardus Elisabeth COUMANS